Brivanib在晚期实体瘤中的II期随机停药试验
本研究为brivanib在7种实体瘤中的II期随机停药试验,595例患者接受12周开放导入期治疗,疾病稳定者随机接受brivanib或安慰剂。软组织肉瘤和卵巢癌满足扩展标准,FGF2阳性肉瘤患者中位PFS为2.8个月对1.4个月(HR 0.58,p=0.08),但FGF2表达并非疗效预测生物标志物。
要点
- Brivanib在软组织肉瘤和卵巢癌中显示活性,安全性可接受。
- FGF2阳性软组织肉瘤患者中位PFS 2.8个月对1.4个月(HR 0.58,p=0.08)。
- FGF2表达按方案定义并非brivanib疗效的预测生物标志物。
核心结论
- Brivanib在软组织肉瘤和卵巢癌中显示活性,安全性可接受。
- 按方案定义的FGF2表达不是brivanib疗效的预测生物标志物。
研究设计与样本
- II期随机停药试验,纳入7种肿瘤类型(软组织肉瘤、卵巢癌、乳腺癌、胰腺癌、非小细胞肺癌、胃/食管癌、移行细胞癌)。
- 12周开放导入期接受brivanib 800 mg每日一次,第12周疾病稳定者随机接受brivanib或安慰剂。
- 共595例患者接受治疗,主要目标为FGF2阳性肿瘤中brivanib对比安慰剂的PFS。
主要发现
- 所有肿瘤类型在第12周随机点均观察到疾病稳定。
- 乳腺癌、胰腺癌、非小细胞肺癌、胃癌和移行细胞癌做出关闭决定;软组织肉瘤和卵巢癌满足扩展标准。
- 53例FGF2阳性软组织肉瘤随机患者中,brivanib组中位PFS 2.8个月,安慰剂组1.4个月(HR 0.58,p=0.08)。
- 全部随机软组织肉瘤患者中,brivanib组中位PFS 2.8个月(95%CI 1.4-4.0),安慰剂组1.4个月(95%CI 1.3-1.6)(HR 0.64,95%CI 0.38-1.07;p=0.09)。
- 36例FGF2阳性卵巢癌随机患者中,brivanib组中位PFS 4.0个月(95%CI 2.6-4.2),安慰剂组2.0个月(95%CI 1.2-2.7)(HR 0.56,95%CI 0.26-1.22);全部随机卵巢癌患者中,brivanib组4.0个月(95%CI 2.6-4.2),安慰剂组2.0个月(95%CI 1.2-2.7)(HR 0.54,95%CI 0.25-1.17;p=0.11)。
临床怎么用
- Brivanib在软组织肉瘤和卵巢癌中显示一定活性,但FGF2表达不能用于筛选获益人群。
- 研究未达到主要终点,FGF2阳性软组织肉瘤PFS差异无统计学显著性(p=0.08)。
局限性
- FGF2阳性亚组样本量较小,统计效能有限。
- 随机停药设计可能影响PFS评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]). PATIENTS AND METHODS: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response to determine if enrolment in a tumour type would continue. The primary objective was progression-free survival (PFS) for brivanib versus placebo in patients with FGF2-positive tumours. RESULTS: A total of 595 patients were treated, and stable disease was observed at the week 12 randomisation point in all tumour types. Closure decisions were made for breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours, the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio [HR]: 0.58, p = 0.08). For all randomised patients with sarcomas, the median PFS was 2.8 months (95% confidence interval [CI]: 1.4-4.0) for those treated with brivanib compared with 1.4 months (95% CI: 1.3-1.6) for placebo (HR = 0.64, 95% CI: 0.38-1.07; p = 0.09). In the 36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was 4.0 (95% CI: 2.6-4.2) months for brivanib and 2.0 months (95% CI: 1.2-2.7) for placebo (HR: 0.56, 95% CI: 0.26-1.22). For all randomised patients with ovarian cancer, the median PFS in those randomised to brivanib was 4.0 months (95% CI: 2.6-4.2) and was 2.0 months (95% CI: 1.2-2.7) in those randomised to placebo (HR = 0.54, 95% CI: 0.25-1.17; p = 0.11). CONCLUSION: Brivanib demonstrated activity in STS and ovarian cancer with an acceptable safety profile. FGF2 expression, as defined in the protocol, is not a predictive biomarker of the efficacy of brivanib.
引用
- Jones RL, Ratain MJ, O'Dwyer PJ, et al. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019. PMID: 31522033. doi:10.1016/j.ejca.2019.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。